Latest News - Inotek Pharmaceuticals

Friday, February 24, 2017 | Conferences, Glaucoma, Inotek Pharmaceuticals

Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the American Glaucoma Society 2017 Annual Meeting

Inotek Pharmaceuticals announced three poster presentations at the American Glaucoma Society 2017 Annual Meeting to be held March 2-5 in Coronado, California. The presentation details are as follows: …

Read the full story

Tuesday, January 03, 2017 | Clinical Trials, Inotek Pharmaceuticals

Inotek Fails Phase 3 Trial of Trabodenoson for Glaucoma

Inotek Pharmaceuticals announced topline results of MATrX-1, the first pivotal phase 3 trial of trabodenoson for the treatment of primary open-angle glaucoma or ocular hypertension. The trial did not …

Read the full story

Wednesday, August 24, 2016 | Clinical Trials, Glaucoma, Inotek Pharmaceuticals

Inotek Announces the Completion of the Recruitment Phase of MuATrX-1, the First Phase 3 Clinical Trial of Trabodenoson for Glaucoma

Inotek Pharmaceuticals announced the completion of the active recruitment phase of MATrX-1, the first pivotal phase 3 trial of trabodenoson for the treatment of glaucoma. Trabodenoson, the compan…

Read the full story

Friday, July 22, 2016 | Patents, Inotek Pharmaceuticals

Inotek Pharmaceuticals Expands Intellectual Property Portfolio with Combination Patent for IOP Lowering

Inotek Pharmaceuticals announced that the United States Patent and Trademark Office issued a composition of matter patent for the combination of the company’s lead product candidate, trabod…

Read the full story

Wednesday, July 13, 2016 | Clinical Trials, Inotek Pharmaceuticals

Inotek Pharmaceuticals Initiates Phase 2 Dose-Ranging Trial of a Fixed-Dose Combination of Trabodenoson and Latanoprost

Inotek Pharmaceuticals announced the initiation of a phase 2 dose-ranging trial of a fixed-dose combination of trabodenoson and latanoprost for the treatment of glaucoma. Trabodenoso…

Read the full story

Tuesday, April 26, 2016 | Conferences, Inotek Pharmaceuticals

Inotek Pharmaceuticals Announces Poster Presentations on Trabodenoson at the ARVO 2016 Annual Meeting

Inotek Pharmaceuticals announced three poster presentations at the Association for Research in Vision and Ophthalmology (ARVO) 2016 Annual Meeting to be held May 1-5 at the Washington State Convention…

Read the full story

Thursday, April 21, 2016 | Clinical Trials, Glaucoma, Inotek Pharmaceuticals

Inotek Announces Publication of Phase 1 Data for Glaucoma Drug Candidate Trabodenoson

Inotek Pharmaceuticals announced the Journal of Ocular Pharmacology and Therapeutics (JOPT) has published the results from its phase 1 dose-escalation trial in healthy adult volunteers of the company&…

Read the full story

Monday, April 11, 2016 | Clinical Trials, Glaucoma, Inotek Pharmaceuticals

Inotek Pharmaceuticals' Phase 2 Data for Trabodenoson in Patients With Glaucoma and Ocular Hypertension Published

Inotek Pharmaceuticals, a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of therapies for ocular diseases, today announced the Journal of Ocular P…

Read the full story